NOL8 Antibody

What is NOL8 and why is it significant for cancer research?

NOL8, also known as Nucleolar Protein 8 or NOP132, is a protein that plays an essential role in the survival of diffuse-type gastric cancer cells. The protein contains an RNA recognition motif (RRM) domain in its amino-terminal region, suggesting a role in RNA binding and processing . Studies have demonstrated that NOL8 is specifically upregulated in diffuse-type gastric cancers compared to intestinal-type gastric cancers . Its expression profile is relatively specific, with significant expression in skeletal muscle but limited expression in other tissues .

The significance of NOL8 in cancer research stems from experimental evidence showing that when NOL8 is knocked down using siRNA in diffuse-type gastric cancer cell lines (St-4, MKN45, and TMK-1), it induces apoptosis in these cells . This suggests NOL8 could be a potential therapeutic target for diffuse-type gastric cancers. Additionally, NOL8 may be involved in regulation of gene expression at the post-transcriptional level or in ribosome biogenesis in cancer cells .

What types of NOL8 antibodies are available for research applications?

Several types of NOL8 antibodies are available for research applications, varying in their binding specificities, reactivity profiles, and applications:

Most commercially available NOL8 antibodies are polyclonal antibodies generated in rabbits, with different epitope specificities targeting various regions of the NOL8 protein, including the C-terminus, N-terminus, and specific amino acid sequences . These antibodies have been validated for various applications including Western blotting, immunohistochemistry, immunofluorescence, and immunoprecipitation.

How should I choose the appropriate NOL8 antibody for my experiment?

Selecting the appropriate NOL8 antibody depends on several critical experimental factors. First, consider the species you're working with - most NOL8 antibodies have been validated for human samples, with some showing cross-reactivity with mouse and rat . If you're working with other species, you may need to confirm predicted reactivity with the manufacturer.

Second, determine which application is most relevant to your research question. Different NOL8 antibodies are optimized for specific techniques:

• For protein detection and quantification, choose antibodies validated for Western blotting

• For localization studies, select antibodies validated for immunohistochemistry (IHC) or immunofluorescence (IF)

• For protein-protein interaction studies, choose antibodies validated for immunoprecipitation (IP)

Third, consider the binding specificity that best aligns with your research focus. C-terminal antibodies like ABIN6263688 and ABIN7185233 detect the C-terminus of NOL8 , while others target specific amino acid regions. This choice is particularly important if you're investigating specific domains or if splice variants are present.

Finally, review validation data provided by manufacturers or in published literature. For NOL8, product information often includes Western blot images showing detection of endogenous NOL8 at approximately 150 kDa, which matches the predicted molecular weight of the protein .

What are the optimal conditions for using NOL8 antibodies in Western blotting?

When optimizing Western blotting protocols for NOL8 detection, several technical considerations can significantly improve results. NOL8 is a relatively large protein with a calculated molecular weight of approximately 132 kDa, though it typically appears at around 150 kDa on SDS-PAGE gels due to post-translational modifications, particularly phosphorylation .

For sample preparation, cell lysis should be performed in a buffer containing phosphatase inhibitors, as NOL8 exists in phosphorylated forms . Standard RIPA buffer supplemented with protease and phosphatase inhibitor cocktails is generally effective. For gel electrophoresis, use lower percentage gels (6-8% acrylamide) or gradient gels to ensure proper resolution of this large protein.

Recommended working dilutions for NOL8 antibodies in Western blotting vary by product:

• For 12043-1-AP, dilutions between 1:2000-1:12000 have been validated

• For NBP1-46849, a concentration of 0.1-1 μg/ml has proven effective

During transfer, longer transfer times or semi-dry systems may be necessary due to the large size of NOL8. Blocking in 5% non-fat milk or BSA in TBST for 1 hour at room temperature is typically sufficient. Primary antibody incubation is recommended overnight at 4°C with gentle agitation.

For detection, HRP-conjugated secondary antibodies with chemiluminescence provide good sensitivity. In validation studies, exposure times of 10-30 seconds have been sufficient to detect endogenous NOL8 in cell lines like HeLa and 293T .

How can I validate the specificity of an NOL8 antibody in my experimental system?

Validating antibody specificity is crucial for ensuring reliable experimental results. For NOL8 antibodies, several complementary approaches are recommended in accordance with best practices in antibody validation .

The knockout/knockdown validation method represents the gold standard. This involves comparing antibody signals in wild-type cells versus cells where NOL8 has been knocked down using siRNA or CRISPR-Cas9 technology. Previous studies have successfully knocked down NOL8 in gastric cancer cell lines (St-4, MKN45, and TMK-1) using siRNA , which could serve as a model system. A properly specific antibody should show significantly reduced or absent signal in the knockdown samples.

Orthogonal validation is another powerful approach, where you compare protein measurements from antibody-based methods with measurements from antibody-independent methods such as mass spectrometry. Additionally, measuring mRNA levels by qPCR can provide supporting evidence when correlated with protein levels detected by the antibody.

Independent antibody validation involves using multiple antibodies targeting different epitopes of NOL8. If multiple antibodies (e.g., those targeting the N-terminus and C-terminus) show similar staining patterns or detection profiles, this increases confidence in specificity . This strategy can be implemented by comparing results from antibodies like ABIN6263688 (C-Term) and N-terminal targeting antibodies.

Genetic strategies involving expression of tagged NOL8 (e.g., with FLAG or His tags) can also provide robust validation. By comparing the detection of the tagged protein with both the NOL8 antibody and an antibody against the tag, you can confirm specificity.

What are the key considerations for optimizing NOL8 immunohistochemistry protocols?

Immunohistochemistry (IHC) for NOL8 requires careful optimization to achieve specific nuclear/nucleolar staining without background. Based on available data, NOL8 is primarily localized to the nucleolus , so appropriate protocol optimization should yield predominantly nucleolar staining in positive cells.

For tissue fixation and processing, standard formalin fixation and paraffin embedding (FFPE) protocols are compatible with most NOL8 antibodies. Antigen retrieval is crucial - heat-induced epitope retrieval (HIER) using citrate buffer (pH 6.0) or EDTA buffer (pH 9.0) for 15-20 minutes has proven effective for NOL8 antibodies.

Working dilutions for IHC applications vary by product:

• For E-AB-17855, dilutions between 1:30-1:150 have been validated for human gastric cancer tissue

• For NBP1-46849, a dilution of 1:1,000 (1μg/ml) has been shown to work on FFPE sections of human ovarian carcinoma

Blocking endogenous peroxidase activity with 3% hydrogen peroxide and employing protein blocking with 5-10% normal serum is recommended to reduce background. As NOL8 is a nuclear protein, using a nuclear counterstain like hematoxylin allows for clear visualization of positive versus negative cells.

For visualization systems, both chromogenic (DAB) and fluorescent detection methods have been validated. When using fluorescent detection, the characteristic nucleolar pattern of NOL8 should be evident and can be confirmed by co-staining with other known nucleolar markers.

How should I address inconsistent staining patterns when using NOL8 antibodies?

Inconsistent staining patterns with NOL8 antibodies can arise from several sources. First, consider whether the inconsistency relates to signal intensity or localization. NOL8 is primarily localized to the nucleolus, so any significant cytoplasmic staining should be viewed with caution and may indicate non-specific binding .

Inconsistent intensity across samples could reflect true biological variation, as NOL8 expression is tissue-specific and upregulated in certain cancer types, particularly diffuse-type gastric cancers . Northern blot analysis has shown that NOL8 is expressed in skeletal muscle but not expressed or hardly detectable in 22 other tissues examined , suggesting narrow expression patterns in normal tissues.

Technical factors may also contribute to inconsistency. Insufficient antigen retrieval can lead to false negatives, especially in FFPE tissues where cross-linking may mask epitopes. Try extending antigen retrieval time or exploring alternative buffers if nucleolar staining is weaker than expected.

Batch-to-batch variability in polyclonal antibodies is another potential factor. All commercially available NOL8 antibodies identified in the search results are polyclonal , which may exhibit greater variability than monoclonal antibodies. Using positive and negative controls in each experimental run can help normalize for this variability.

If inconsistencies persist, consider validating with a different NOL8 antibody targeting a different epitope. Comparing results from C-terminal and N-terminal antibodies can be particularly informative. Additionally, correlating IHC results with Western blot data from the same samples can help determine whether the issue is technique-specific.

Why might my Western blot show multiple bands when probing for NOL8?

The appearance of multiple bands in Western blots probing for NOL8 requires careful interpretation. NOL8 has a calculated molecular weight of approximately 132 kDa but is typically observed at around 150 kDa due to post-translational modifications . When additional bands appear, several explanations should be considered.

Post-translational modifications represent a primary consideration. NOL8 exists in phosphorylated forms, as demonstrated through protein phosphatase analysis coupled with Western analysis . If your sample preparation does not adequately preserve these modifications (e.g., lack of phosphatase inhibitors), you may observe bands at different molecular weights corresponding to differentially modified forms.

Alternative splicing is another potential explanation. While the search results don't specifically mention NOL8 splice variants, many nuclear proteins undergo alternative splicing. Review literature and genomic databases to determine if NOL8 isoforms have been reported in your species of interest.

Proteolytic degradation can generate fragments that are detected by the antibody, particularly if the samples were not properly handled or if protease inhibitors were insufficient. Fresh preparation of samples with adequate protease inhibitors may resolve this issue.

Cross-reactivity with related proteins is a possibility with polyclonal antibodies. All available NOL8 antibodies in the search results are polyclonal , which might recognize epitopes shared with other proteins containing similar domains, particularly the RNA recognition motif (RRM) that NOL8 possesses.

To address this issue, include appropriate controls such as NOL8 knockdown samples or recombinant NOL8 protein. If multiple bands persist, consider using antibodies targeting different epitopes to determine which bands represent true NOL8 signal.

How can I accurately interpret quantitative differences in NOL8 expression across different experimental conditions?

Accurate quantification of NOL8 expression differences requires careful attention to experimental design and data analysis. When comparing NOL8 levels across conditions (e.g., normal versus cancer tissues or treated versus untreated cells), several approaches can enhance reliability.

First, ensure appropriate loading controls are used. For Western blotting, housekeeping proteins like β-actin or GAPDH are common, but nuclear loading controls such as lamin B may be more appropriate for a nucleolar protein like NOL8. For IHC quantification, normalization to total cell number or nuclear area is essential.

Statistical analysis should account for biological and technical variability. Include at least three biological replicates per condition and consider technical replicates for methods with higher variability. When comparing multiple conditions, appropriate statistical tests (e.g., ANOVA with post-hoc tests) should be applied with corrections for multiple comparisons.

Consider the dynamic range and linearity of your detection method. For Western blotting, ensure signals fall within the linear range of detection by performing dilution series with known concentrations of sample. For densitometry analysis, use software that corrects for background and does not saturate signal intensity.

For IHC quantification, developing a scoring system that accounts for both staining intensity and percentage of positive cells can provide more nuanced data than binary positive/negative classification. For example, an H-score system (0-300) calculated by multiplying staining intensity (0-3) by percentage of positive cells (0-100%) has been used in many studies of nuclear proteins.

How can NOL8 antibodies be utilized in studying cancer biology and potential therapeutic targets?

NOL8 antibodies serve as valuable tools for investigating the role of this protein in cancer biology, particularly in gastric cancer research. The discovery that NOL8 is specifically upregulated in diffuse-type gastric cancers and plays an essential role in cancer cell survival has positioned it as a potential therapeutic target .

For target validation studies, NOL8 antibodies can be used in combination with knockdown approaches. Previous research has demonstrated that transfection of siRNA specific to NOL8 into diffuse-type gastric cancer cells (St-4, MKN45, and TMK-1) effectively reduced expression of this gene and induced apoptosis . Western blotting with NOL8 antibodies provides crucial confirmation of successful knockdown at the protein level.

Immunohistochemical analysis of patient samples using NOL8 antibodies can help establish clinical correlations. By evaluating NOL8 expression levels across different cancer subtypes, stages, and grades, researchers can determine whether NOL8 has potential as a diagnostic or prognostic biomarker. The E-AB-17855 antibody has been specifically verified for IHC in human gastric cancer samples .

For exploring NOL8's mechanistic role, co-immunoprecipitation studies using NOL8 antibodies can identify protein interaction partners. NOL8 contains an RNA recognition motif and acts as a nucleolar anchoring protein for DDX47 , suggesting it may participate in RNA processing complexes. IP-grade antibodies like 12043-1-AP, which has been validated for immunoprecipitation , are suitable for such studies.

In drug development pipelines, NOL8 antibodies can assist in high-throughput screening assays to identify compounds that modulate NOL8 expression or function. Following treatment with candidate compounds, Western blotting or immunofluorescence with NOL8 antibodies can detect changes in protein levels or subcellular localization.

What are the best practices for using NOL8 antibodies in co-localization studies with other nucleolar markers?

Co-localization studies of NOL8 with other nucleolar proteins can provide insights into its functional associations within the nucleolus. Given that NOL8 is specifically localized to the nucleolus , carefully designed co-localization experiments can reveal its positioning relative to functionally distinct nucleolar compartments.

For immunofluorescence co-localization studies, several antibodies including ABIN6263688 and 12043-1-AP have been validated for immunofluorescence applications . When designing co-staining protocols, select primary antibodies raised in different host species (e.g., rabbit anti-NOL8 with mouse anti-fibrillarin) to enable simultaneous detection with species-specific secondary antibodies.

The nucleolus contains distinct functional compartments including the fibrillar center (FC), dense fibrillar component (DFC), and granular component (GC). Co-staining NOL8 with markers of these compartments provides functional context:

• Fibrillarin or UBF for the dense fibrillar component

• RNA polymerase I for the fibrillar center

• B23/nucleophosmin for the granular component

For image acquisition, confocal microscopy is recommended to achieve the optical sectioning necessary for accurate co-localization analysis within the three-dimensional nucleolar structure. Z-stack imaging with appropriate step sizes (typically 0.3-0.5 μm) provides complete volumetric data.

Quantitative co-localization analysis should extend beyond visual assessment. Calculate coefficients such as Pearson's correlation coefficient, Manders' overlap coefficient, or intensity correlation quotient using specialized image analysis software. Values closer to 1 indicate higher degrees of co-localization.

To control for random co-localization, include appropriate controls such as co-staining with proteins known to occupy distinct nucleolar regions or non-nucleolar compartments. Additionally, perform channel shift controls by artificially offsetting one channel relative to another to establish baseline correlation values.

How can biophysics-informed modeling be integrated with antibody experiments to design better NOL8-targeting reagents?

The integration of biophysics-informed modeling with experimental antibody data represents an emerging approach for developing optimized antibody reagents with customized specificity profiles. This approach combines computational modeling with experimental validation to design antibodies with enhanced properties for research and potentially therapeutic applications.

Biophysics-informed models can be trained on data from antibody selection experiments to identify distinct binding modes associated with specific ligands or epitopes . For NOL8 research, this approach could help develop antibodies with higher specificity for particular domains or conformational states of the protein.

The process begins with experimental data collection. Phage display experiments involving antibody selection against diverse combinations of NOL8 epitopes or closely related proteins would generate training data . These experiments would provide information about which antibody sequences bind to specific epitopes with high affinity and specificity.

Based on these predictions, the model can generate novel antibody variants not present in the initial library, customized for specific applications . For example, antibodies could be designed to specifically recognize post-translationally modified forms of NOL8 or to discriminate between highly similar regions in NOL8 and related proteins.

Experimental validation follows, testing the binding properties of the designed antibodies through standard approaches like ELISA, Western blotting, and surface plasmon resonance. The results feed back into the model, creating an iterative optimization process.

This integrative approach addresses a significant challenge in antibody research - the limited control over specificity profiles in traditional selection methods. By combining computational design with experimental validation, researchers can develop NOL8 antibodies with precisely defined binding properties for specialized research applications.

How might next-generation sequencing and AI approaches enhance NOL8 antibody development and validation?

Next-generation sequencing (NGS) and artificial intelligence (AI) are poised to transform antibody development and validation processes for targets like NOL8. These technologies address traditional limitations of antibody production while creating new possibilities for enhanced specificity and functionality.

NGS enables comprehensive analysis of antibody repertoires following selection processes like phage display. Rather than isolating and characterizing a limited number of individual antibody clones, NGS can analyze millions of sequences simultaneously, providing a landscape view of all potential binders . For NOL8 antibody development, this could reveal subtle patterns in sequence preferences for antibodies targeting different epitopes.

Combining NGS data with AI-driven approaches enables more sophisticated analysis of antibody-antigen interactions. Machine learning models can identify sequence patterns associated with specific binding properties that might not be apparent through conventional analysis . For example, AI could predict which antibody sequences will specifically recognize phosphorylated versus non-phosphorylated forms of NOL8.

Biophysics-informed models can disentangle multiple binding modes associated with specific epitopes, even when these epitopes are chemically very similar . This capability is particularly valuable for NOL8, which contains domains like the RNA recognition motif that share similarities with other RNA-binding proteins.

Beyond development, AI approaches can also enhance validation. By analyzing patterns in validation data across multiple antibodies and applications, models can predict potential cross-reactivity issues or optimal conditions for specific applications without exhaustive experimental testing.

Looking forward, the emergence of language models trained on antibody sequences shows promise for addressing germline bias - a challenge in antibody development. Models like AbLang-2 are optimized for predicting non-germline residues and suggesting diverse valid mutations . This capability could be valuable for designing NOL8 antibodies with improved specificity and reduced background binding.

What role might NOL8 antibodies play in understanding the relationship between nucleolar stress and cancer progression?

NOL8 antibodies represent critical tools for investigating the relationship between nucleolar stress and cancer progression, particularly in gastric cancer where NOL8 plays a documented role. The nucleolus serves as a central hub for cellular stress responses, and disruptions in nucleolar function are increasingly recognized as contributing factors in cancer development.

NOL8's essential role in the survival of diffuse-type gastric cancer cells suggests it may function as a stress-adaptive protein . The finding that NOL8 knockdown promotes apoptosis in gastric cancer cell lines indicates it might protect cancer cells from stress-induced cell death pathways . NOL8 antibodies can help map changes in NOL8 expression, phosphorylation state, and localization under various stress conditions to elucidate these mechanisms.

Immunofluorescence studies using NOL8 antibodies can track nucleolar reorganization during stress responses. Under conditions like nutrient deprivation, hypoxia, or chemotherapeutic treatment, the nucleolus undergoes morphological changes that affect ribosome biogenesis and other functions. Tracking NOL8 during these responses could reveal whether it participates in stress-adaptive nucleolar remodeling.

Co-immunoprecipitation experiments with NOL8 antibodies can identify stress-dependent protein interactions. NOL8 contains an RNA recognition motif and acts as a nucleolar anchoring protein for DDX47 , suggesting roles in RNA processing. Determining whether these interactions change under stress conditions could reveal regulatory mechanisms.

Chromatin immunoprecipitation (ChIP) studies, if NOL8 has DNA-binding capabilities, could examine whether it associates with specific genomic regions under stress conditions. Such experiments would require validation of NOL8 antibodies for ChIP applications, which was not explicitly mentioned in the search results but could be established through appropriate testing.

Translational studies combining tissue microarrays of patient samples with NOL8 immunohistochemistry could correlate NOL8 expression patterns with clinical parameters such as tumor grade, stage, and patient outcomes. Such correlations might identify patient subgroups where NOL8-targeted therapies could be most effective.

By utilizing NOL8 antibodies in these diverse applications, researchers can build a comprehensive understanding of how nucleolar stress responses, mediated in part by NOL8, contribute to cancer progression and potentially identify new therapeutic vulnerabilities.